Literature DB >> 16896590

[Therapy-associated late effects after irradiation of malignant diseases in childhood and adolescence. Feasibility analyses of a prospective multicenter register study].

Tobias Bölling1, Andreas Schuck, Christian Rübe, Stefan Hesselmann, Hildegard Pape, Karin Dieckmann, Barbara Pöllinger, Rolf-Dieter Kortmann, Irene Speiser-Held, Frank-Michael Meyer, Carmen Martini, Branka Asadpour, Beate Timmermann, Jörn D Beck, Thorsten Langer, Marios Paulides, Bernhard Schmidt, Normann Willich.   

Abstract

BACKGROUND AND
PURPOSE: Radiogenic late effects in children and adolescents have been evaluated retrospectively in most analyses, with small patient numbers. The German Group of Pediatric Radiation Oncology (APRO) has generated a concept for a prospective evaluation of radiation-associated late effects in childhood. The aim of this study was to evaluate the feasibility of a nationwide central database for the documentation of radiation parameters and side effects of all children treated within therapy protocols of the German Society of Pediatric Oncology and Hematology (GPOH). PATIENTS AND METHODS: A study center has been implemented in Muenster, the documentation has started in July 2001 in few centers in a pilot phase. Since February 2004 the documentation is done countrywide. Detailed documentation forms have been designed for treatment parameters and for doses applied at organs at risk. Furthermore, a uniform toxicity documentation, according to the RTOG/EORTC criteria, was chosen. Patients were reported from the study centers of the GPOH to the study center. All information was collected and analyzed in the study center.
RESULTS: Till July 31, 2005, 438 documentations of radiation and 579 toxicity documentations of side effects have been collected in the study center. 46 centers for radiotherapy in Germany and one center each in Austria and in Switzerland took part in the documentation. The quality of documentation regarding completeness and plausibility fulfilled the expected criteria in most cases. This feasibility analysis showed that important information about organ dose levels and side effects was documented in a large number of patients (Figures 1 and 2).
CONCLUSION: This prospective evaluation of radiotherapy and radiogenic side effects in children and adolescents will allow correlating doses at organs at risk and the incidence of acute and late sequelae in Germany. Further documentations and a longer follow-up are necessary to obtain powerful results.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16896590     DOI: 10.1007/s00066-006-1517-9

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  11 in total

1.  Evaluation of side effects after radiotherapy in childhood and adolescence: from retrospective case reports to a prospective, multicentric and transnational approach.

Authors:  Normann Willich; Iris Ernst; Hildegard Pape; Christian Rübe; Beate Timmermann; Branka Asadpour; Rolf-Dieter Kortmann; Tobias Bölling
Journal:  Strahlenther Onkol       Date:  2009-08       Impact factor: 3.621

2.  Secondary neoplasms after Wilms' tumor in Germany.

Authors:  Nasenien Nourkami; Rhoikos Furtwängler; Muhannad Alkassar; Norbert Graf
Journal:  Strahlenther Onkol       Date:  2009-08       Impact factor: 3.621

Review 3.  Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia.

Authors:  Rachid Haidar; Hani Mhaidli; Ali T Taher
Journal:  Eur Spine J       Date:  2010-03-05       Impact factor: 3.134

4.  Comparison of different adjuvant radiotherapy approaches in childhood bladder/prostate rhabdomyosarcoma treated with conservative surgery.

Authors:  Frank Heinzelmann; Daniela Thorwarth; Ulf Lamprecht; Theodor W Kaulich; Jörg Fuchs; Guido Seitz; Martin Ebinger; Rupert Handgretinger; Michael Bamberg; Martin Weinmann
Journal:  Strahlenther Onkol       Date:  2011-10-29       Impact factor: 3.621

Review 5.  Curative treatment for central nervous system medulloepithelioma despite residual disease after resection. Report of two cases treated according to the GPHO Protocol HIT 2000 and review of the literature.

Authors:  Klaus Müller; Isabella Zwiener; Helmut Welker; Eberhard Maass; Rudolf Bongartz; Frank Berthold; Torsten Pietsch; Monika Warmuth-Metz; André von Bueren; Stefan Rutkowski
Journal:  Strahlenther Onkol       Date:  2011-10-28       Impact factor: 3.621

6.  Comparison of the effects of melatonin and genistein on radiation-induced nephrotoxicity: Results of an experimental study.

Authors:  Emine Canyilmaz; Gonca Hanedan Uslu; Zumrut Bahat; Mustafa Kandaz; Sevdegul Mungan; Emel Haciislamoglu; Ahmet Mentese; Adnan Yoney
Journal:  Biomed Rep       Date:  2015-11-24

7.  Hepatotoxicity after liver irradiation in children and adolescents : results from the RiSK.

Authors:  Pascal Rösler; Hans Christiansen; Rolf-Dieter Kortmann; Carmen Martini; Christiane Matuschek; Frank Meyer; Christian Rübe; Thorsten Langer; Raphael Koch; Hans Theodor Eich; Normann Willich; Diana Steinmann
Journal:  Strahlenther Onkol       Date:  2014-12-09       Impact factor: 3.621

8.  Perioperative intensity-modulated brachytherapy for refractory orbital rhabdomyosarcomas in children.

Authors:  Rainer Joachim Strege; György Kovács; Jens Eduard Meyer; Detlef Holland; Alexander Claviez; Maximilian H Mehdorn
Journal:  Strahlenther Onkol       Date:  2009-12       Impact factor: 3.621

9.  Long-term renal toxicity in children following fractionated total-body irradiation (TBI) before allogeneic stem cell transplantation (SCT).

Authors:  Johanna Gerstein; Andreas Meyer; Karl-Walter Sykora; Jörg Frühauf; Johann H Karstens; Michael Bremer
Journal:  Strahlenther Onkol       Date:  2009-11-10       Impact factor: 3.621

10.  Study protocol of the German "Registry for the detection of late sequelae after radiotherapy in childhood and adolescence" (RiSK).

Authors:  Tobias Bolling; Andreas Schuck; Hildegard Pape; Christian Rube; Barbara Pollinger; Beate Timmermann; Rolf D Kortmann; Karin Dieckmann; Normann Willich
Journal:  Radiat Oncol       Date:  2008-04-21       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.